Exclusive prescription spray product to treat Xerostomia will compete in $1 Billion US Market
RED BANK, N.J., Dec. 11 /PRNewswire/ -- Bi-Coastal Pharmaceutical Corp. announced today that it has acquired the US marketing rights to Aquoral(TM) artificial saliva. Aquoral(TM) is a lipid based artificial saliva spray product that is currently the only Prescription spray product marketed in the United States to treat Xerostomia. The total US market for products treating Xerostomia was estimated at $1 Billion in 2007. The product is sold in a 40ml (1.4 fl. oz.) spray bottle that if used as directed is a 2 month supply. Aquoral(TM) has already received overwhelming acceptance by physicians as well as patients suffering with Xerostomia. The sales and marketing of Aquoral(TM) will begin by Bi-Coastal to the Pharmaceutical trade channels immediately.
Bi-Coastal Pharmaceutical Corp. is a leading Sales, Marketing and Consulting company founded in 1982 and based in Red Bank, New Jersey. Since 2001, Bi-Coastal has secured product sales in excess of $650 Million. Bi-Coastal is currently finalizing its multi-faceted sales and marketing plans for Aquoral(TM) that will include an aggressive trade and physician advertising campaign, telemarketing, direct mail and other programs to physicians as well as a detail sales force initially targeting the Dental, Oncology, Rheumatology and Managed Care markets.
Ralph Massa, Jr., Bi-Coastal Pharmaceutical Corp.'s President and Chief Operating Officer stated the following, "I am pleased to announce the acquisition of Aquoral(TM) and confident that we will achieve significant sales levels well within the first year of marketing the product. Aquoral(TM) will soon be a trusted and proven household name to treat Xerostomia as it is an extremely effective and easy to use product with no known adverse effects. We look forward to the official re-launch of Aquoral(TM) to the trade at the upcoming ECRM conference in Destin, Florida next month as well as discussing many other products that will be a part of Bi-Coastal's exciting product portfolio in 2009."
For more information please contact: Ralph Massa, Jr. President and Chief Operating Officer Bi-Coastal Pharmaceutical Corp. 130 Maple Avenue Red Bank, New Jersey 07701 www.bicoastalpharm.com Tel-(732) 530-6606 Ext 132 Fax-(732) 530-1521 e-mail: firstname.lastname@example.org
|SOURCE Bi-Coastal Pharmaceutical Corp.|
Copyright©2008 PR Newswire.
All rights reserved